cbdMD (YCBD) Return on Sales (2016 - 2026)

cbdMD (YCBD) posted Return on Sales of 0.0% for Q4 2025, up 60.82% sequentially from 0.0% in Q3 2025, and little changed YoY from 0.0% in Q4 2024.

cbdMD (YCBD) Return on Sales (2016 - 2026) Analysis & Trends

cbdMD has reported Return on Sales for 10 years, with the latest figure at 0.0% in Q4 2025.

Quarterly Return on Sales changed 0.0% year-over-year to 0.0% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
Return on Sales improved to 0.0% in Q4 2025 per YCBD's latest filing, from 0.0% in the prior quarter.
Over five years, Return on Sales peaked at 0.0% in Q2 2024 and troughed at 0.04% in Q2 2022.
A 5-year average of 0.01% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
The sharpest annual moves came in 2021 and 2023: Return on Sales declined 2 bps in 2021, then grew 3 bps in 2023.
Over 5 years, Return on Sales stood at 0.02% in 2021, then surged by 67 bps to 0.01% in 2022, then jumped by 71 bps to 0.0% in 2023, then surged by 102 bps to 0.0% in 2024, then slumped by 2012 bps to 0.0% in 2025.
According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 0.0% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Haleon	44.42 Bn	43.46 Bn	-	-
2	Teva Pharmaceutical Industries	43.71 Bn	40.06 Bn	2.15 Bn	0.00%
3	Zoetis	32.56 Bn	30.88 Bn	1.05 Bn	0.00%
4	Takeda Pharmaceutical	28.63 Bn	22.84 Bn	5.10 Bn	0.00%
5	United Therapeutics	22.08 Bn	19.41 Bn	683.80 Mn	0.00%
6	Viatris	18.92 Bn	18.03 Bn	1.46 Bn	0.00%
7	Neurocrine Biosciences	15.48 Bn	15.09 Bn	935.80 Mn	0.00%
8	Elanco Animal Health	11.99 Bn	11.46 Bn	798.00 Mn	0.00%
9	Dr Reddys Laboratories	10.15 Bn	9.99 Bn	-	-
10	cbdMD	5.41 Mn	3.29 Mn	3.04 Mn	0.00%

Download Data